Intended for healthcare professionals


Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund

BMJ 2017; 356 doi: (Published 03 January 2017) Cite this as: BMJ 2017;356:i6864
  1. Ingrid Torjesen
  1. London

The liver cancer treatment sorafenib should not be available routinely in the NHS in England, but it should continue to be available through the Cancer Drugs Fund, the National Institute for Health and Care Excellence (NICE) has recommended in draft guidance.

NICE originally published guidance in 2010 saying that sorafenib was not cost effective, even though it had considered the drug under its higher cost per quality adjusted life year (QALY) criterion for end of life treatments and …

View Full Text

Log in

Log in through your institution


* For online subscription